Kornimate/medical-research-clean huggingface dataset:
using of irradiated amnion dressing for the treatment of skin ulcer

Conditions: Ulcer

Summary: to evaluate the using of a commercial product of dried human amniotic membrane sterilized by gamma irradiation for the treatment of skin ulcer.

dried human amniotic membrane patches were obtained from national center for radiation research and technology, egypt, under commercial name rege pro.

Eligibility criteria:
inclusion criteria: * patients have unhealing ulcer exclusion criteria: * must stop other line of treatment

Keywords: skin ulcer, human amniotic membrane, treatment
ptfe covered stents versus naked stents in the tips (transjugular intra-hepatic porto-systemic shunt)

Conditions: Cirrhotic Portal Hypertension

Summary: transjugular intrahepatic portosystemic shunts (tips) have been increasingly used for the treatment of complications of portal hypertension in patients with cirrhosis. the initial experiment of the tips was reported during the 1990s with stents of various brands, manufacture and sizes, but all "non covered", thus owing the pseudointimal hyperplasia growing inside the stent, which progressively decreases the diameter of the shunt and thus its efficacy. since the beginning of the 2000s, appeared stents known as "covered" by polytetrafluoroethylene (ptfe) designed to reduce the obstruction rate and thus the frequency shunt revisions. however, these stents are, on average, 2.5 times more expensive than the non covered stents and the cost-effectiveness ratio of the tips according to the type of stents used has not been assessed. the aim of this multicentric and randomized study is to assess the cost-effectiveness ratio of these 2 principles of tips, the one using stents covered by ptfe, relatively expensive but seldom becoming obstructed, and the other using non covered stents, less expensive than ptfe but requiring regular gestures of redilatation. population concerned: patients with a cirrhotic portal hypertension responsible for: * recurrent variceal bleeding * refractory ascite (or hydrothorax)


Eligibility criteria:
inclusion criteria: * presence of a cirrhosis as documented by previous liverbiopsy or typical clinical signs * indication validated of the tips (bavéno iv), except not-controlled acute hemorrhagic : * recurrent variceal bleeding after failure of the usual pharmacological and endoscopic methods * refractory or recurrent ascites or difficult to treat * refractory hydrothorax exclusion criteria: * non cirrhotic htp * child c ≥12 * complete portal vein thrombosis * usual contra-indication for tips : * known or suspected hepatocarcinoma by increase of the alpha-foetoprotein \>100 ui/ml associated with the presence of at least one hepatic nodule * cardiac insufficiency defined by a ventricular fraction of ejection \< 40% with the echocardiography preliminary to the procedure * pulmonary arterial hypertension (pap \> 40 mmhg) * hepatic polycystosis * intra-hepatic bile ducts dilatation, * spontaneous clinical recurrent hepatic encephalopathy

Keywords: cirrhosis, stic tips, portal hypertension, transjugular intrahepatic portosystemic shunt , stents, ptfe cirrhotic htp
developing and evaluating the yorkshire dialysis decision aid

Conditions: Chronic Kidney Failure

Summary: the purpose of this research is to develop a patient decision aid in paper and web formats to help patients with chronic kidney disease make informed dialysis treatment decisions.

this research will develop and evaluate a paper and web resource known as a decision-aid to help patients make informed decisions about dialysis treatment. the yorkshire dialysis decision aid (yodda) will help patients' with chronic kidney disease make informed decisions between haemodialysis and peritoneal dialysis choices by a) re-writing dialysis information in a more meaningful way for patients, b) restructuring information to make this difficult decision more manageable, and c) using prompts to help patients imagine the choices' consequences. the research will assess the acceptability of a patient decision aid in paper and web versions to patients and their carers, and its impact on patients choices about dialysis. the programme of research included: a survey using qualitative methods of patients with chronic kidney disease and professionals providing predialysis services to develop the yorkshire dialysis decision aid content, and integration within usual predialysis care practices. a before-and-after study was carried out to evaluate the acceptability of the yodda-booklet to patients with sustained deterioration of kidney function making dialysis decision across the yorkshire and humber region, uk. an experimental study was carried out on-line to evaluate the acceptability of three versions of yodda-web (yodda; yodda+values tasks; yodda_patient videos) to people, or carers of people, with kidney disease. the study was advertised with flyers within uk renal units and notices on the national kidney federation's website and members' magazine.

Eligibility criteria:
inclusion criteria: adult patients with chronic kidney disease and carers of people with chronic kidney diseae who are making decisions about dialysis treatments. - exclusion criteria: those not literate in english -

Keywords: dialysis chronic kidney failure informed choice patient decision making decision aid
nano-crystalline megestrol acetate for adjuvant treatment in high-risk head and neck squamous cell carcinoma after surgery.

Conditions: Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors

Summary: this study is a prospective, randomized, parallel-controlled clinical trial, with the primary objective to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to standard treatment alone for adjuvant therapy in patients with high-risk squamous cell carcinoma of the head and neck (excluding nasopharyngeal carcinoma) after surgery.


Eligibility criteria:
inclusion criteria: * ≥18 years at the time of enrollment. * eastern cooperative oncology group (ecog) performance status score of 0-2. * life expectancy ≥6 months. * patients with histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, larynx, and hypopharynx). * patients who have undergone surgery for head and neck squamous cell carcinoma within 6 weeks and are assessed postoperatively as having high-risk factors requiring radiotherapy ± chemotherapy. exclusion criteria: * suffering from tumors in areas other than the oral cavity, oropharynx, larynx, and hypopharynx, such as nasopharyngeal carcinoma or other unknown primary head and neck tumors. * having any condition that affects gastrointestinal absorption, such as dysphagia, malabsorption, or uncontrollable vomiting; currently undergoing tube feeding or parenteral nutrition. * suffering from anorexia due to neurosis, mental illness, or difficulty eating due to pain. * suffering from acquired immune deficiency syndrome (aids).
a study of pep02 in combination with 5-fluorouracil (5-fu) and leucovorin (lv) in advanced solid tumors

Conditions: Solid Tumor

Summary: this trial is a multi-center, open-label, phase i, dose escalation study of pep02 (liposomal encapsulated irinotecan) in combination with 5-fu and lv in patients with advanced solid tumors.

in this study, the initial starting dose of pep02 is 60 mg/m2, and was escalated by increments of 20 mg/m2 between dose levels. 5-fu and lv was given as 24-hour infusion via an implanted central venous catheter, with dose fixed at 2000 mg/m2 and 200 mg/m2, respectively. pep02 was administered on day 1; 5-fu/lv was started after the end of pep02 infusion on day 1 and also on day 8. treatment repeated every 3 weeks and it was regarded as one cycle of treatment.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed solid tumor which was locally advanced or metastatic and had failed to standard chemotherapy or no standard treatment was available * ecog performance status 0 or 1 * with normal organ and marrow function exclusion criteria: * have had major surgery, chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin c) prior to entering the study or have not recovered from toxicities due to previous treatment * with known or suspicious primary or secondary brain tumors * history of allergic reactions attributed to compounds of similar chemical or biologic composition to pep02, 5-fu or leucovorin * hbsag+ or anti-hcv+ patients with splenomegaly (defined as spleen size \> 11 cm in ct scan) * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, and history of symptomatic congestive heart failure of functional class ii or more (new york heart association) and ischemic heart diseases (i.e. myocardial infarction or angina pectoris), cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * pregnant or breast feeding females (a pregnancy test must be performed on all females who are of child-bearing potential before entering the study and the result must be negative) * had received irinotecan treatment
analysis of cutaneous and hematologic disorders by high-throughput nucleic acid sequencing

Conditions: Cutaneous Lymphoma; Other Skin Disorders; Mycosis Fungoides; Cutaneous T-cell Lymphoma

Summary: the goal of this study is to identify genetic changes associated with the initiation, progression, and treatment response of response of cutaneous and hematologic disorders using recently developed high-throughput sequencing technologies. the improved understanding of the genetic changes associated with cutaneous and hematologic disorders may lead to improved diagnostic, prognostic and therapeutic options for these disorders.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * patient meets the clinical and/or pathologic criteria for the cutaneous or hematologic disorder being examined. * patient is willing to provide skin biopsies and five 10 ml tubes of peripheral blood. exclusion criteria: - less than 18 years of age
alcohol: thiamine and or magnesium 1

Conditions: Alcohol Withdrawal; Lactic Acidosis; Vitamin B1 Deficiency; Magnesium Deficiency; Wernicke Encephalopathy

Summary: patients who suffer alcohol use disorder (aud) have a 30-80% incidence of thiamine deficiency causing wernicke's encephalopathy (we). intravenous (iv) thiamine replacement is standard practice in the treatment of alcoholic patients presenting to the accident \& emergency (a\&e) department, however routine co-supplementation with magnesium (administered iv as magnesium sulphate ), which is required as a co-factor for thiamine in some metabolic processes, e. g. on the activity of the enzyme transketolase in red blood cells, is not routine practice in the treatment of these patients. without correction of concomitant magnesium deficiency there may be impaired utilisation of thiamine resulting in a failure to treat we. this study is designed to determine if administration of magnesium to aud patients affects red cell transketolasae and serum lactate concentrations by itself, or only acts to increase the effect of thiamine on the activity of this enzyme.

this is a 3- arm randomised, open label, controlled study in a cohort of alcoholic patients admitted through a\&e. patients will be randomised to concurrent infusion of one of the following: * arm 1: iv thiamine * arm 2: iv magnesium sulphate followed by delayed iv thiamine * arm 3: iv thiamine and iv magnesium sulphate thiamine will be administered as iv pabrinex, a compound preparation which also contains b vitamins and vitamin c. administration of iv pabrinex is standard care in this patient group and magnesium sulphate is routinely co-administered at glasgow royal infirmary.

Eligibility criteria:
inclusion criteria: * written informed consent * male or non-pregnant or breastfeeding females ≥18 years of age for women of child-bearing potential a negative pregnancy test will be required prior to treatment. (women of non-childbearing potential are defined as those defined as women who are post-menopausal or permanently sterilised (e.g. hysterectomy, tubal occlusion, bilateral salpingectomy). • chronic alcohol dependence as confirmed by * fast questionnaire * gmaws scale exclusion criteria: * unable to give consent * less than 18 years of age * chronic renal or hepatic failure/hepatic encephalopathy (investigator assessment as documented in past medical history i.e. clinical portal.) * known hypersensitivity or previous allergy to any of the active substances in either trial medication, or to excipients * severe concurrent medical condition that would prevent participation in study procedures (e.g. myasthenia gravis, clinically significant cardiac disease, or cardiac failure with severe pulmonary oedema)
human papillomavirus in menstrual blood

Conditions: Human Papillomavirus

Summary: the investigators tried to know whether a virus causing cervical cancer could be detected in menstrual blood and to set up a experimental setting to detect the virus.


Eligibility criteria:
inclusion criteria: * premenopausal women with hsil at pap test or high-risk hpv exclusion criteria: * suspicious cancer

Keywords: hpv menstrual blood hpv detection using menstrual blood
heart rate variability in response to metformin challenge

Conditions: Fibromyalgia; Mitochondrial Diseases; Movement Disorders; Diabetes Mellitus, Type 2

Summary: diseases caused by brain energy supply defects can be innate (fibromyalgia secondary to familial mitochondrial disorders) or acquired (tardive dyskinesia or weight gain associated with prolonged antipsychotic use). patients with these possible mitochondrial disorders will provide a baseline resting heart rate sample, ingest low-dose metformin (500 mg), and then provide an additional sample 2 hours later.

doctors need to develop tests which inexpensively and reliably evaluates brain metabolism. current diagnostic tests sample other tissues which often run on different fuels (fats), utilize unproven and often insensitive brain imaging scanners, or sequence thousands to millions of base-pairs of dna. all of these tests are expensive. none of these tests accurately or completely capture the interactions between the 1000s of proteins involved in brain metabolism. the investigators suspect that mathematical analysis of the resting heart rate may provide some insight into brain metabolism. the brain controls heart rate in response to changes in blood pressure and blood gases like carbon dioxide and oxygen. tight control of heart rate is necessary to make sure that the brain has the right mix of fuel and air. because the brain can't respond instantly to changes in its fuel supply, this system acting as a biological carburetor has a natural oscillatory rhythm that can be monitored just like frequencies on the radio. the investigators propose to amplify these rhythms by modestly metabolically stressing the brain with metformin, a inhibitor of complex 1 in the mitochondria.

Eligibility criteria:
inclusion criteria: either chronic neurogenic pain meeting american college of rheumatology criteria for fibromyalgia or previous/current exposure to antipsychotic medications exclusion criteria: * recent infection, * renal failure, * pre-existing cardiac disease, * chronic obstructive pulmonary disease * inability to participate in informed consent, * lack of transport to return home from study site, * severe fasting intolerance or hypoglycemia, * history of stroke-alike episode, * uncontrolled migraine or cyclic vomiting, * diabetes on insulin or sulfonylurea, * non-english speaker, * medications with strong effects on baseline heart rate variability

Keywords: metformin mitochondria complex 1 fibromyalgia neurogenic pain diabetes tardive dyskinesia heart rate variability
local paclitaxel delivery for sfa disease

Conditions: Atherosclerosis; Angioplasty; Peripheral Arterial Disease

Summary: to see if restenosis rates of superficial femoral artery atherosclerosis with percutaneous techniques can be improved using paclitaxel.

treatment of superficial femoral artery atherosclerosis with percutaneous techniques is hindered by high restenosis rates. paclitaxel inhibits restenosis in coronary arteries, and a few studies suggest it may be effective in reducing restenosis rates in peripheral arteries. the investigators hypothesize that delivering paclitaxel through an irrigating catheter will be superior in preventing restenosis.

Eligibility criteria:
inclusion criteria: * all subjects between 18 and 80 years of age with symptomatic claudication (rutherford category 1-6) with tasc ii type a, b, or c lesions will be invited to participate (23, 24). * patients must be on appropriate pharmacologic therapy for pad including antiplatelet agents and lipid-lowering therapy. exclusion criteria: * life expectancy \<1year * acute limb ischemia * anatomy not amenable to percutaneous revascularization * inability to provide informed consent * renal insufficiency (creatinine clearance \<40ml/min calculated using cockcroft-gault equation) * prisoners * pregnant or lactating women

Keywords: atherosclerosis angioplasty peripheral arterial disease
a study of xenical (orlistat) in overweight and obese adolescents

Conditions: Obesity

Summary: this 2 arm study will assess the effect of xenical on body mass index (bmi)in obese or overweight adolescents. patients will be randomised into one of 2 groups; both groups will undergo a regimen of mildly hypocaloric diet and physical exercise, but one group will also receive xenical 120mg po tid. the anticipated time on study treatment is 1 year, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adolescent patients, 12-14 years of age * overweight or obese exclusion criteria: * age \ 14 years * bmi in normal range
evaluation of the effectiveness of spa treatment in swieradow zdroj with special regard to the action of radon waters

Conditions: Osteoarthritis; Degenerative Disc Disease

Summary: observation conducted during the 21 days of treatment in the health resort of swieradow-zdroj. in a treatment of applied therapy: radon therapeutic baths and inhalations, kinesiotherapy. study group with degenerative joints and disc disease participating in therapy. the control group was selected by the spa workers, also suffering from a degenerative disease of the movement organs not using the spa's treatment base. in both of these groups, appropriate pre- and post-treatment studies were performed.

the observation was conducted during 21 days of medicinal stays in the health resort of swieradow-zdroj. the treatment included a comprehensive therapy: radon therapeutic baths and inhalations, kinesiotherapy. the study group consisted of patients with degenerative joints and disc disease participating in therapy. on the day of admission to the spa the patients were subjected to subjective and objective examination. laboratory tests (lipids profile, crp, smear blood morphology, tas- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. in addition, before and after treatment, standard scales were used to assess pain intensity: mcgill scale and vas scale and anxiety and depression levels - hads scale. the control group was selected by the spa workers, also suffering from a degenerative disease of the movement organs not using the spa's treatment base. in this group also made the same study.

Eligibility criteria:
inclusion criteria: * the presence of degenerative joints and/or disc disease; * age range 40-60 years; * the written consent to participate in research; * no impediment to comprehensive treatment at the spa. exclusion criteria: * the lack of consent to participate in research; * the age under 40 and over 60 years; * the presence of diseases constituting a contraindication to therapy (compatible with the standard list of indications and contraindications to spa therapy); * the presence of metabolic diseases.
phase 2 study of tlk286 in platinum resistant advanced epithelial ovarian cancer

Conditions: Ovarian Neoplasms

Summary: the purpose of this study is to determine the effectiveness and safety of tlk286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.


Eligibility criteria:
inclusion criteria * histologic diagnosis of ovarian cancer * recurrent or persistent disease following primary therapy * measurable disease * prior treatment with at least one but no more than three prior chemotherapy regimens * resistant or refractory to platinum-based chemotherapy * at least 18 years of age * good performance status (ecog 0 to 1) * adequate liver, renal and bone marrow function exclusion criteria * pregnant or currently breast feeding * treatment with chemotherapy or immunotherapy within four weeks * prior radiation to the whole pelvis
a transdiagnostic, self-guided internet intervention ("velibra") for waitlist patients with anxiety disorders

Conditions: Panic Disorder With Agoraphobia; Panic Disorder Without Agoraphobia; Generalized Anxiety Disorder; Social Anxiety Disorder

Summary: the project's aim is to investigate the effect of a transdiagnostic, self-guided, internet-based cognitive behavioral therapy program in waitlist patients with anxiety disorders.

patients who fulfill the inclusion criteria and are interested in psychotherapy are offered participation in the study to bridge the waiting time for face-to-face psychotherapy. after obtaining informed consent, a pre-treatment assessment is conducted. then, participants are provided access to velibra, an internet-based cognitive behavioral therapy program which they can work through at their own pace. while velibra is a self-guided program, participants are supported by study personnel during four assessments at four time points: pre-treatment, mid-treatment (after the first three velibra modules), post-treatment and at the one-month follow-up. the investigators expect improvements on the primary as well as the secondary outcomes. furthermore, the investigators are interested in studying the acceptability of velibra and whether positive changes already become observable after the first three modules, i.e., at the mid-treatment assessment.

Eligibility criteria:
inclusion criteria: * diagnosis of panic disorder with or without agoraphobia, social anxiety disorder, or generalized anxiety disorder * knowledge of german that is sufficient for engaging with the treatment and responding to the questionnaires * written informed consent * internet access exclusion criteria: * diagnoses of severe mental comorbidities (e.g., schizophrenia, severe major depression, borderline personality disorder) * acute suicidality * started or changed anxiolytic pharmacotherapy recently (currently or in the past four weeks)

Keywords: cognitive behavioral therapy internet intervention administrative-supported anxiety panic disorder social anxiety disorder generalized anxiety disorder computerized cbt anxiety disorders velibra psychotherapy